Current regulatory analysis, FDA enforcement trends and practical GMP compliance guidance. Written from primary regulatory sources - the same approach we bring to every course.
303 warning letters. A 59% increase. One in three citing environmental monitoring failures. Five deliberate falsification cases in Q1. And a first-ever AI warning letter. Here is what five years of FDA enforcement data tells pharmaceutical professionals heading into the second half of 2026 - and the six areas that carry the highest inspection risk right now.
26 of 44 FDA warning letters in FY2025 cited CAPA deficiencies. Retraining as the only corrective action is no longer accepted. Here are the four citation patterns FDA inspectors document most frequently and what a compliant CAPA system actually requires.
On January 14, 2026 the FDA and EMA jointly released 10 guiding principles for AI in drug development. Draft EU GMP Annex 22 goes further - the first binding framework for AI in pharmaceutical manufacturing. Here is what both documents require and what your site needs to do before Annex 22 finalises.
You can outsource the work. You cannot outsource the responsibility. Five Q1 2026 warning letters cited deliberate falsification at contract labs and CROs. In each case FDA held the application holder accountable. Here is what a compliant CMO oversight programme looks like and what the 2026 enforcement data means for your quality agreements and audit programme.
Failure to thoroughly investigate OOS results under 21 CFR 211.192 has been the number one FDA 483 citation category for four consecutive years. Two 2026 warning letters confirm the stakes are not declining. Here is the complete two-phase investigation framework and the four citation patterns FDA consistently documents.
On April 2, 2026, FDA issued the first warning letter in history containing a section explicitly titled "Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing." The manufacturer used AI agents to create drug product specifications, SOPs and master production records without quality unit review. The company subsequently ceased drug production. Here is what every QA team needs to understand.
FDA sent 303 drug warning letters in FY2025 - a 59% increase from FY2024. The same four CFR sections have held the top four positions in every inspection year from 2021 through 2024. Understanding why sites keep failing these same requirements - and what to do about it - is one of the most commercially valuable things a QA professional can know.
Since August 2023 the Contamination Control Strategy has been mandatory for every sterile manufacturing site supplying the EU market. Two years of post-implementation inspections have revealed consistent patterns - the most common CCS gaps being found by EMA and national competent authorities, and how to build a CCS that genuinely de-risks the inspection.
Three years after the 2022 draft, FDA finalised the Computer Software Assurance guidance on September 24, 2025 - with a further update in February 2026 aligning it with the QMSR and ISO 13485:2016. An industry survey in early 2024 found that 31% of pharmaceutical professionals had never heard of CSA. Here is everything you need to know.
Human errors account for approximately 50% of all quality incidents in pharmaceutical manufacturing. Yet "human error" remains the most over-used and least useful root cause conclusion in the industry. FDA has made its position clear in warning letters: attributing a deviation to human error without identifying the underlying systemic cause is not a thorough investigation. It is the beginning of one.
21 CFR Part 211 governs facilities, equipment, personnel, production, laboratory controls and records for every pharmaceutical manufacturer supplying the US market. The same four sections from Part 211 have held the top four FDA inspection observation positions for four consecutive years. Here is what effective online Part 211 training should cover.
EU GMP Annex 1 (2022) introduced the most significant changes to sterile manufacturing expectations in fourteen years. The training obligation under Section 2.1 is explicit and documented. Two years into the implementation period, here is what inspectors are finding and what effective Annex 1 training must cover.
GMP training records are a cGMP requirement under 21 CFR 211 and EU GMP Chapter 2. A completion certificate from a credible training programme is part of the documented evidence that an inspector expects to see. Here is how to choose a pharmaceutical GMP certificate programme that prepares you for real regulatory decisions.
Data integrity is the second most cited area in FDA drug warning letters. The December 2018 FDA guidance covers eighteen specific regulatory interpretations that every QA and QC professional must understand. Here is what the guidance actually requires and where manufacturers most commonly fall short.
ICH Q9(R1) was revised in 2023, adding two significant requirements not in the 2005 original - formality proportionate to risk, and explicit guidance on managing subjectivity and bias in risk assessments. Here is what the revision means for pharmaceutical quality risk management programmes.
FDA finalised the CSA guidance on September 24, 2025 and updated it in February 2026. The final guidance explicitly includes AI and machine learning systems, cloud and SaaS deployments, and cybersecurity requirements. Here is what every validation programme must address now.